The table below shows Ultragenyx Pharmaceutical Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$466.00M
-$414.00M
-$475.00M
-$380.46M
-$338.69M
-$132.22M
Capital expenditure
$6.00M
$7.00M
$44.00M
$116.12M
$73.09M
$43.91M
Investing cash flow
$236.00M
-$18.00M
$168.00M
-$291.65M
-$195.37M
-$179.12M
Dividends paid
-
-
-
-
RARE operating cash flow (10-K history)
Ultragenyx Pharmaceutical Inc. reported operating cash flow of -$466.00M for fiscal year 2025. That is down 12.6% from -$414.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$160.97M (FY 2016) to -$466.00M. Figures come from the company's audited annual reports as filed with the SEC.